Oral GLP-1 orforglipron shows cardiovascular non-inferiority to insulin glargine

The ACHIEVE-4 phase 3 trial compared oral orforglipron with insulin glargine in adults with type 2 diabetes, obesity or overweight, and established cardiovascular or chronic kidney disease. Over a median 2-year follow-up, the trial reported non-inferiority for major adverse cardiovascular events (MACE-4) with orforglipron versus insulin glargine (HR 0.84, 95% CI 0.59-1.20). The trial also reported more gastrointestinal adverse events with orforglipron but less clinically significant hypoglycaemia compared with insulin glargine.

Most relevant for: Adults with type 2 diabetes and obesity or overweight who have established cardiovascular disease or chronic kidney disease and are at increased cardiovascular risk.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.